Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 36, Issue 2, 2012, Pages 81-87

  McMillin, Gwendolyn A ^a,b,c   Davis, Rebecka ^b   Carlisle, Heidi ^a   Clark, Chantry ^a   Marin, Stephanie J ^b   Moody, David E ^d  

^a ARUP LABORATORIES   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DRUG METABOLITE; NALOXONE; NORBUPRENORPHINE; DRUG DERIVATIVE; GLUCURONIDE;

ANALYTIC METHOD; ARTICLE; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; LABORATORY DIAGNOSIS; METHODOLOGY; URINE;

BUPRENORPHINE; CHROMATOGRAPHY, LIQUID; GLUCURONIDES; HUMANS; NALOXONE; SPECIMEN HANDLING; TANDEM MASS SPECTROMETRY;

EID: 84862621692     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkr020     Document Type: Article

References (38)

1. Cowan, A.; Lewis, J.W.; MacFarlane, I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 1977, 60, 537-545.
2. Ling, W.; Charuvastra, C.; Collins, J.F.; Batki, S.; Brown, L.S.; Kintaudi, P. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998, 93, 475-486.
3. Johnson, R.E.; Chutuape, M.A.; Strain, E.C.; Walsh, S.L.; Stitzer, M.L.; Bigelow, G.E. A comparison of levomethadol acetate, buprenorphine and methadone for opioid dependence. N. Engl. J. Med. 2000, 343, 1290-1297.
4. Drug Addiction Treatment Act of 2000. Public Law 106-310, 2000.
5. McCance-Katz, E.F. Office-based buprenorphine treatment for opioid-dependent patients. Harv. Rev. Psychiatry 2004, 12, 321-338.
6. Heit, H.A.; Gourlay, D.L. Buprenorphine-new tricks with an old molecule for pain management. Clin. J. Pain 2008, 24, 93-97.
7. Iribarne, C.; Picart, D.; Dreano, Y.; Bail, J.-P.; Berthou, F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver micrsomes. Life Sci. 1997, 60, 1953-1964.
8. Moody, D.E.; Slawson, M.H.; Strain, E.C.; Laycock, J.D.; Spanbauer, A.C.; Foltz, R.L. A liquid chromatographic-electrospray ionizationtandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem. 2002, 306, 31-39.
9. Chang, Y.; Moody, D.E. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab. Lett. 2009, 3, 101-107.
10. Rouguieg, K.; Picard, N.; Sauvage, F.L.; Gaulier, J.M.; Marquet, P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab. Dispos. 2010, 38, 40-45.
11. Picard, N.; Cresteil, T.; Djebli, N.; Marquet, P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 2005, 33, 689-695.
12. Chang, Y.; Moody, D.E.; McCance-Katz, E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 2006, 34, 440-448.
13. Moody, D.E.; Chang, Y.; Huang, W.; McCance-Katz, E.F. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin. Pharmacol. Toxicol. 2009, 105, 211-215.
14. Cone, E.J.; Gorodetzky, C.W.; Yousefnejad, D.; Buchwald, W.F.; Johnson, R.E. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 1984, 12, 577-581.
15. Cone, E.J.; Gorodetzky, C.W.; Yousefnejad, D.; Darwin, W.D. 63Ni Electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces. J. Chromatogr. 1985, 337, 291-300.
16. Huang, W.; Moody, D.E.; McCance-Katz, E.F. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 2006, 28, 245-251.
17. Kacinko, S.L.; Jones, H.E.; Johnson, R.E.; Choo, R.E.; Concheiro-Guisan, M.; Huestis, M.A. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin. Chem. 2009, 55, 1177-1187.
18. Hand, C.W.; Ryan, K.E.; Dutt, S.K.; Moore, R.A.; O'Connor, J.; Talbot, D.; McQuay, H.J. Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic. J. Anal. Toxicol. 1989, 13, 100-104.
19. Debrabandere, L.; Van Boven, M.; Daenens, P. High-performance liquid chromatography with electrochemical detection of buprenorphine and its major metabolite in urine. J. Chromatogr. 1991, 564, 557-566.
20. Blom, Y.; Bondesson, U.; Anggard, E. Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring. J. Chromatogr. 1985, 338, 89-98.
21. Lisi, A.M.; Kazlauskas, R.; Trout, G.J. Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. J. Chromatogr. B 1997, 692, 67-77.
22. Vincent, F.; Bessard, J.; Vacheron, J.; Mallaret, M.; Bessard, G. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. J. Anal. Toxicol. 1999, 23, 270-279.
23. George, S.; George, C.; Chauhan, M. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. Forensic Sci. Int. 2004, 143, 121-125.
24. Kronstrand, R.; Selden, T.G.; Josefsson, M. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 2003, 27, 464-470.
25. Fox, E.J.; Tetlow, V.A.; Allen, K.R. Quantitative analysis of buprenorphine and norbuprenorphine in urine using liquid chromatography tandem mass spectrometry. J. Anal. Toxicol. 2006, 30, 238-244.
26. Hegstad, S.; Khiabani, H.Z.; Øiestad, E.L.; Berg, T.; Christophersen, A.S. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. J. Anal. Toxicol. 2007, 31, 214-219.
27. Cirimele, V.; Kintz, P.; Lohner, S.; Ludes, B. Enzyme immunoassay validation for the detection of buprenorphine in urine. J. Anal. Toxicol. 2003, 27, 103-105.
28. Böttcher, M.; Beck, O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J. Anal. Toxicol. 2005, 29, 769-776.
29. Miller, E.I.; Torrance, H.J.; Oliver, J.S. Validation of Immunalysisw microplate ELISA for the detection of buprenorphine and its metabolite norbuprenorphine in urine. J. Anal. Toxicol. 2006, 30, 115-119.
30. Wang, G.J.; Vincent, M.; Rodrigues, W.; Agrawal, A.; Moore, C.; Barhate, R.; Abolencia, E.; Coulter, C.; Soares, J.; Zheng, Y.F.; Taylor, C.; Morjana, N. Development and GC-MS validation of a highly sensitive recombinant G6PDH-based homogenous immunoassay for the detection of buprenorphine and norbuprenorphine in urine. J. Anal. Toxicol. 2007, 31, 377-382.
31. Hull, M.J.; Bierer, M.F.; Griggs, D.A.; Long, W.H.; Nixon, A.L.; Flood, J.G. Urinary buprenorphine concentrations in patients treated with Suboxonew as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J. Anal. Toxicol. 2008, 32, 516-521.
32. Kronstrand, R.; Nystrom, I.; Andersson, M.; Gunnarsson, L.; Hagg, S.; Josefsson, M; Ahlner, J. Urinary detection times and metabolite/ parent compound ratios after a single dose of buprenorphine. J. Anal. Toxicol. 2008, 32, 586-593.
33. Wu, M.Y.; Wang, Y.S.; Lin, C.C.; Lin, D.L.; Su, L.W.; Huang, M.H.; Liu, R.H. An empirical study on the selection of analytes and corresponding cutoffs for immunoassay and GC-MS in a two-step test strategy-buprenorphine example. Analyst 2009, 134, 1848-1856.
34. Kintz, P. Deaths involving buprenorphine: a compendium of cases. Forensic Sci. Int. 2001, 121, 65-69.
35. Lai, S.H.; Yao, Y.J.; Lo, D.S.T. A survey of buprenorphine related deaths in Singapore. Forensic Sci. Int. 2006, 162, 80-86.
36. Feng, S.X.; ElSohly, M.A.; Duckworth, D.T. Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 2001, 25, 589-593.
37. ElSohly, M.A.; Gul, W.; Feng, S.X.; Murphy, T.P. Hydrolysis of conjugated metabolites of buprenorphine-II. The quantitative enzymatic hydrolysis of norbuprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 2005, 29, 570-573.
38. Tenore, P.L. Advanced urine toxicology testing. J. Addict. Dis. 2010, 29, 436-448.